Lyell Immunopharma, Inc. (LYEL)

NASDAQ: LYEL · Real-Time Price · USD

16.93

+0.20 (1.17%)

At close: May 28, 2026, 4:00 PM EDT

16.83

-0.10 (-0.56%)

After-hours: May 28, 2026, 4:00 PM EDT

Lyell Immunopharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	May '26 May 28, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Cap	393	654	189	493	866	1,879
Market Cap Growth	215.40%	246.60%	-61.70%	-43.11%	-53.91%	-
Enterprise Value	180.59	448.81	-130.81	3.35	289.02	1,331
Last Close Price	16.93	30.78	12.80	38.80	69.40	154.80
PS Ratio	12668.15	18169.60	3093.82	3789.86	10.23	176.41
PB Ratio	1.43	2.64	0.49	0.75	1.04	2.02
P/TBV Ratio	1.17	2.12	0.44	0.74	1.03	1.13
EV/Sales Ratio	5825.38	12466.90	-2144.42	25.80	3.41	124.94
EV/EBITDA Ratio	-	-	0.39	-	-	-
EV/EBIT Ratio	-	-	0.36	-	-	-
EV/FCF Ratio	-	-	0.80	-	-	-
Debt / Equity Ratio	0.14	0.17	0.13	0.09	0.08	0.07
Net Debt / Equity Ratio	-0.78	-0.83	-0.83	-0.75	-0.69	-0.59
Net Debt / EBITDA Ratio	0.87	0.80	0.94	2.16	3.41	2.73
Net Debt / FCF Ratio	1.60	1.36	1.96	2.94	2.98	2.86
Asset Turnover	0.00	0.00	0.00	0.00	0.08	0.01
Quick Ratio	6.88	5.00	6.89	15.82	17.29	13.15
Current Ratio	7.23	5.28	7.06	16.07	17.59	13.40
Return on Equity (ROE)	-94.43%	-86.98%	-66.10%	-31.53%	-20.77%	-30.36%
Return on Assets (ROA)	-74.22%	-64.85%	-57.82%	-29.27%	-18.12%	-21.10%
Return on Invested Capital (ROIC)	-497.30%	-458.31%	-292.85%	-113.41%	-50.21%	-58.16%
Return on Capital Employed (ROCE)	-84.82%	-74.04%	-62.25%	-30.57%	-18.88%	-22.15%
Buyback Yield / Dilution	-38.93%	-30.74%	-4.18%	-1.58%	-81.79%	-925.18%
Total Shareholder Return	-38.93%	-30.74%	-4.18%	-1.58%	-81.79%	-925.18%

Updated May 6, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q